Chlorpromazine-Induced Relapse of Tourette Syndrome in a Patient With Intellectual Disability, Attention Deficit Hyperactivity Disorder, and Schizophrenia.
attention deficit hyperactivity disorder
chlorpromazine
schizophrenia
tourette syndrome
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
30 Sep 2020
30 Sep 2020
Historique:
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by recurrent multiple motor and vocal tics that last for at least one year and follow a waxing and waning course. A fundamental step in the pathophysiology of TS is the hyperactivity of dopaminergic system leading to increased dopamine release in the cortical-basal ganglia-thalamo-cortical (CBGTC) circuits, thereby providing the rationale for treatment with dopamine receptor, in particular D2, antagonists. Although antipsychotics have shown considerable efficacy against tics in most patients, there have been cases of paradoxical onset of tics in individuals without history, and relapse or exacerbation of tics in individuals with a history of tic disorders upon initiation of antipsychotics. Here we report a case of an individual with intellectual disability, attention deficit hyperactivity disorder (ADHD), and schizophrenia, who experienced a relapse of TS symptoms after initiation of chlorpromazine therapy.
Identifiants
pubmed: 33145137
doi: 10.7759/cureus.10732
pmc: PMC7599051
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e10732Informations de copyright
Copyright © 2020, Maqsood et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurol Sci. 2018 Jun 15;389:76-80
pubmed: 29433809
Am J Psychiatry. 2002 Aug;159(8):1329-36
pubmed: 12153825
Neuropsychiatr Dis Treat. 2015 Mar 30;11:873-4
pubmed: 25848286
Clin Neuropharmacol. 2006 May-Jun;29(3):163-4
pubmed: 16772818
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13307-12
pubmed: 16131542
Neurology. 2003 Feb 25;60(4):606-11
pubmed: 12601100
J Clin Psychiatry. 2002 Dec;63(12):1184-5
pubmed: 12530422
Neuropsychopharmacology. 2008 May;33(6):1239-51
pubmed: 17987065
Transl Psychiatry. 2018 Aug 2;8(1):143
pubmed: 30072700
Neurology. 2001 Oct 23;57(8):1383-8
pubmed: 11673576
Mov Disord. 1997 May;12(3):402-7
pubmed: 9159736
Pediatrics. 1998 Jul;102(1 Pt 1):14-9
pubmed: 9651407
Lancet Psychiatry. 2015 Jan;2(1):68-87
pubmed: 26359614
Neurology. 2000 Mar 28;54(6):1310-5
pubmed: 10746603
West J Med. 1992 Feb;156(2):198-9
pubmed: 1536082
J Comp Neurol. 2010 Feb 1;518(3):277-91
pubmed: 19941350
CNS Drugs. 2018 Oct;32(10):917-938
pubmed: 30121819
Am J Psychiatry. 1986 Sep;143(9):1176-7
pubmed: 2875666
Neurol Sci. 2005 Jun;26(2):137-9
pubmed: 15995832
Eur Child Adolesc Psychiatry. 2007 Jun;16 Suppl 1:15-23
pubmed: 17665279